Objective

Biotech business models are rapidly evolving to cope inter alia with challenges in accessing first-in-class science, establishment of academic partnerships and securing funding for translational research and drug discovery. Evotec is a global drug discovery company with a full range of small-molecule focused capabilities from target validation to late-stage clinical development. To improve the quality and speed of innovation at the interphase of academia and biotech, Evotec developed a novel risk-share paradigm of collaboration with academic centers of excellence –termed the Academic BRIDGE- to significantly shorten the time from drug development idea to commercially attractive preclinical projects. With LAB282, LAB150 and more recently LAB591, Evotec has teamed up with the leading universities across the globe to build both disease-focused and disease-agnostic BRIDGEs. Insights from the first full year of operations within these operations – with a focus on small molecule drug discovery- will be shared. Evotec Dr Mark Slack VP Academic Partnerships Mark.Slack@evotec.com